Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 396

Sort by

Sort Order Select

Journal Articles

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Blood blood.2025030113.

https://doi.org/10.1182/blood.2025030113

Published: 2025

Includes: Supplemental data

Journal Articles

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia

Blood blood.2025030177.

https://doi.org/10.1182/blood.2025030177

Published: 2025

Includes: Supplemental data

Journal Articles

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Evangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V. Kostopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos

Blood (2025) 145 (20): 2353–2360.

https://doi.org/10.1182/blood.2024027686

Published: 2025

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Efstathios Kastritis, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 7021.

https://doi.org/10.1182/blood-2024-203941

Published: 2024

Journal Articles

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Ioannis Ntanasis-Stathopoulos, Eirini Katodrytou, Evdoxia Hatjiharissi, Emmanouil Spanoudakis, Vasiliki Douka, Despina Fotiou, Vasiliki Labropoulou, Dimitra Dalampira, Vasiliki Spiliopoulou, Theodosia Papadopoulou, Dimitrios Christoulas, Panagiotis Malandrakis, Anthi Bouchla, Vasiliki Pappa, Efstathios Kastritis, Evangelos Terpos, Meletios Dimopoulos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 6988.

https://doi.org/10.1182/blood-2024-206900

Published: 2024

Journal Articles

Prognostic Impact of T(11;14) in Newly Diagnosed Patients with Multiple Myeloma in the Era of Modern Treatments

Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, Panagiotis Malandrakis, Alexandros Briasoulis, Charalampos Filippatos, Despina Fotiou, Magdalini Migkou, Vasiliki Spiliopoulou, Foteini Theodorakakou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 6968.

https://doi.org/10.1182/blood-2024-202627

Published: 2024

Journal Articles

Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Charalampia Kyriakou, Carlyn Rose Tan, Niels Abildgaard, Michel Delforge, Dorotea Beatriz Eugenia Fantl, Cristian M Seehaus, Emilie Carneiro, Cristina João, Saad Z. Usmani

Blood (2024) 144 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2024-202539

Published: 2024

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, Panagiotis Malandrakis, Efstathios Kastritis, Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 4696.

https://doi.org/10.1182/blood-2024-194398

Published: 2024

Journal Articles

Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma

Ioannis Ntanasis-Stathopoulos, Maria Douka, Vassilis Koutoulidis, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Irene Solia, Nikolaos Kanellias, Efstathios Kastritis, Meletios Dimopoulos, Evangelos Terpos, Lia-Angela Moulopoulos

Blood (2024) 144 (Supplement 1): 4724.

https://doi.org/10.1182/blood-2024-209797

Published: 2024

Journal Articles

Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes

Maria Gavriatopoulou, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Maria Douka, Vasiliki Spiliopoulou, Charalampos Filippatos, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos, Lia-Angela Moulopoulos

Blood (2024) 144 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2024-209637

Published: 2024

Journal Articles

A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, Panagiotis Malandrakis, Pantelis Rousakis, Chrysanthi Panteli, Evangelos Eleutherakis-Papaiakovou, Vasiliki Spiliopoulou, Georgia Dimitrakopoulou, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Nikolaos Kanellias, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

Blood (2024) 144 (Supplement 1): 490.

https://doi.org/10.1182/blood-2024-194090

Published: 2024

Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Blood (2024) 144 (Supplement 1): 487.

https://doi.org/10.1182/blood-2024-199550

Published: 2024

Journal Articles

Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group

Blood (2024) 144 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2024-203519

Published: 2024

Journal Articles

The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations

Eleni Kalafati, Kostantina Taouxi, Ourania Theologi, Nefeli Mavrianou Koutsoukou, Ioannis Kollias, Christine-Ivy Liacos, Alexandra Papadimou, Katerina Chrisostomidou, Maria Gavriatopoulou, Meletios Dimopoulos, Evangelos Terpos, Nicholas P. Anagnou, Efstathios Kastritis, Tina Bagratuni

Blood (2024) 144 (Supplement 1): 1603.

https://doi.org/10.1182/blood-2024-205460

Published: 2024

Journal Articles

Genomic Characterization of Ibrutinib-Resistant Waldenström's Macroglobulinemia

Tina Bagratuni, Christos Vlachos, Maria Sakkou, Ioannis Kollias, Ourania Theologi, Nefeli Mavrianou Koutsoukou, Christine-Ivy Liacos, Kostantina Taouxi, Alexandra Papadimou, Katerina Chrisostomidou, Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, Meletios-Athanasios Dimopoulos

Blood (2024) 144 (Supplement 1): 1600.

https://doi.org/10.1182/blood-2024-200652

Published: 2024

Journal Articles

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

Despina Fotiou, Foteini Theodorakakou, Irene Solia, Maria Gavriatopoulou, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Erasmia Psimenou, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 6966.

https://doi.org/10.1182/blood-2024-203853

Published: 2024

Journal Articles

Bone Disease Burden Does Not Seem to Impact Overall Survival in Newly Diagnosed Patients with Multiple Myeloma - a Detailed Imaging Analysis on 119 Patients

Evangelos Terpos, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, Stylianos Mavropoulos-Papoudas, Maria Douka, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Lia-Angela Moulopoulos, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 6941.

https://doi.org/10.1182/blood-2024-209786

Published: 2024

Journal Articles

Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, Vasiliki Spiliopoulou, Despina Fotiou, Foteini Theodorakakou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania Tsitsilonis, Meletios Dimopoulos, Evangelos Terpos

Blood (2024) 144 (Supplement 1): 361.

https://doi.org/10.1182/blood-2024-209826

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Prognostic Impact of T(11;14) in Newly Diagnosed Patients with Multiple Myeloma in the Era of Modern Treatments

Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma

Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes

A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group

The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations

Genomic Characterization of Ibrutinib-Resistant Waldenström's Macroglobulinemia

Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis

Bone Disease Burden Does Not Seem to Impact Overall Survival in Newly Diagnosed Patients with Multiple Myeloma - a Detailed Imaging Analysis on 119 Patients

Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only